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Gene expression in mammalian organisms is regulated at multiple levels, including DNA accessibility for
transcription factors and chromatin structure. Methylation of CpG dinucleotides is thought to be involved in
imprinting and in the pathogenesis of cancer. However, the relevance of methylation for directing tissue-
specific gene expression is highly controversial. The cyclin A1 gene is expressed in very few tissues, with high
levels restricted to spermatogenesis and leukemic blasts. Here, we show that methylation of the CpG island of
the human cyclin A1 promoter was correlated with nonexpression in cell lines, and the methyl-CpG binding
protein MeCP2 suppressed transcription from the methylated cyclin A1 promoter. Repression could be relieved
by trichostatin A. Silencing of a cyclin A1 promoter-enhanced green fluorescent protein (EGFP) transgene in
stable transfected MG63 osteosarcoma cells was also closely associated with de novo promoter methylation.
Cyclin A1 could be strongly induced in nonexpressing cell lines by trichostatin A but not by 5-aza-cytidine. The
cyclin A1 promoter-EGFP construct directed tissue-specific expression in male germ cells of transgenic mice.
Expression in the testes of these mice was independent of promoter methylation, and even strong promoter
methylation did not suppress promoter activity. MeCP2 expression was notably absent in EGFP-expressing
cells. Transcription from the transgenic cyclin A1 promoter was repressed in most organs outside the testis,
even when the promoter was not methylated. These data show the association of methylation with silencing of
the cyclin A1 gene in cancer cell lines. However, appropriate tissue-specific repression of the cyclin A1
promoter occurs independently of CpG methylation.
Gene expression in higher organisms is initiated by the in-
teraction of the basal transcriptional machinery with the dou-
ble-stranded DNA helix of a eukaryotic promoter (for a re-
view, see reference 6). The process of this interaction critically
depends on the chromatin structure surrounding the DNA and
the abundance and binding ability of the relevant accessory
transcription factors (14, 35). Both mechanisms, a nonpermis-
sive chromatin structure as well as either the absence of im-
portant transcriptional activators or the presence of repressors,
can inhibit gene transcription. A permissive chromatin struc-
ture contains acetylated histones that allow unfolding of the
nucleosome, making it accessible to transcription factors (48,
56, 59). Conversely, the deacetylation of histones leads to re-
pression of transcriptional activity. A wide variety of transcrip-
tional repressors (e.g., Mad-Max complexes) are known to
recruit corepressors, such as mSin3A, N-CoR, and SMRT (2).
These corepressors are associated with several other proteins,
including histone deacetylases 1 and 2 (HDAC1 and HDAC2),
which remove acetyl moieties from specific lysine residues on
histones H3 and H4 (50). The positively charged lysine resi-
dues interact with the DNA and render it inaccessible to the
transcription machinery (57).
Recently, the methylation of CpG dinucleotides has been
demonstrated to mediate transcriptional repression by recruit-
ing histone deacetylases (44, 47). HDAC activity is relocated
by family members of the methylated CpG binding domain
(MBD) proteins (19). Methylation of DNA has long been
associated with the regulation of gene expression, and physio-
logical DNA methylation patterns are essential for embryogen-
esis (36, 67). Abnormalities in CpG methylation are involved in
tumorigenesis and senescence (7, 24, 27). The role of methyl-
ation in the silencing of genes in cancer cells and especially in
cancer cell lines is well documented (1). Methylation of a
tumor suppressor gene (e.g., p16ink4A) is closely related to
transcriptional repression of its expression, and the inhibition
of DNA methylation can lead to reexpression and to altered
tumor growth characteristics (3). While studies have implied
that methylation is only a secondary event in gene silencing
(11), other investigators have suggested that the methylation
itself is the primary event in transcriptional repression in cell
lines (7).
In contrast to the presumed role of methylation in cell lines,
its relevance in directing tissue-specific expression in healthy
organisms is highly controversial (53, 60). A correlation be-
tween methylation and nonexpression has been documented
for several genes (9, 34, 62), but no such correlation exists for
other genes (21, 58). A DNA methylation profile for the mouse
skeletal a-actin promoter showed that expression of the gene
was appropriately repressed in several organs, although the
promoter was not methylated (61). On the other hand, consis-
tent with the idea that methylation can suppress transcription,
the authors did not find expression in organs with strong CpG
methylation of the a-actin promoter. These studies suggest
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that methylation is not necessary for transcriptional repression
in many organs. However, the role of CpG methylation found
in organs without expression of the analyzed gene is unclear.
Methylation might be critically involved in transcriptional re-
pression, it could act as a secondary layer of repression, or
methylation could be an epiphenomenon essentially unin-
volved in gene silencing.
We have started to determine the regulation of expression of
the cyclin A1 gene, a gene that is physiologically expressed at
high levels in pachytene spermatocytes and at much lower
levels in hematopoietic progenitor cells (54, 66). Also, very
high levels of cyclin A1 have been found in leukemic cells
harvested from individuals with acute myeloid leukemia and
from myeloid leukemia cell lines (64, 66). In contrast, very low
expression at the mRNA level is observed in most nonleuke-
mic, adherent cell lines (64). We have recently cloned the
promoter region of cyclin A1 and determined that several GC
boxes are essential for promoter activity (42). In addition, the
promoter is transactivated by c-myb (43). Surprisingly, in con-
trast to the highly restricted expression of the cyclin A1 gene in
vivo, we found the promoter to be very active in transient
transfections in all cell types and cell lines tested so far (42, 43;
unpublished data). Since the gene expression pattern is highly
restricted in vivo, we concluded that either the isolated pro-
moter fragment (;1.3 kb) missed an important repressor bind-
ing site or mechanisms that alter the chromatin structure are
essential for directing tissue-specific expression in vivo.
We therefore carefully analyzed cyclin A1 promoter regula-
tion in cell lines and in mice that were transgenic for a cyclin
A1 promoter-enhanced green fluorescent protein (EGFP)
construct and obtained the following results. The CpG island
of the endogenous cyclin A1 promoter is heavily methylated in
adherent cell lines. Methylation of the cyclin A1 promoter in
cancer cell lines correlates with transcriptional silencing, and
MBD family members are expressed in these cell lines and
might be involved in transcriptional repression of the methyl-
ated cyclin A1 promoter. Cyclin A1 gene expression could be
induced in nonexpressing HeLa cells by inhibitors of deacety-
lation but not by inhibitors of methylation alone. A fragment
containing 1.3 kb upstream of the cyclin A1 transcriptional
start site was sufficient to direct tissue-specific expression in the
testes of transgenic mice. Interestingly, methylation was not
necessary to repress the transgenic promoter in most organs of
the transgenic mice. In addition, methylation of the cyclin A1
promoter was not sufficient to inhibit testis-specific gene ex-
pression. MeCP2 expression was very low in EGFP-expressing
male germ cells. Our study provides evidence that methylation
of the cyclin A1 promoter correlates with transcriptional re-
pression in cell lines, but tissue-specific expression of cyclin A1
in vivo is mediated by methylation-independent mechanisms.
MATERIALS AND METHODS
DNA constructs. The cyclin A1 promoter-EGFP expression plasmid was con-
structed by inserting a 1,444-bp (21299 to 1145) fragment of the cyclin A1
promoter (42) into the BglII and HindIII sites of the promoterless EGFP-1
plasmid (Clontech). The cyclin A1 promoter-luciferase reporter construct con-
tained a 335-bp fragment of the cyclin A1 promoter (2190 to 1145) cloned into
the promoter position of PGL3-Basic (Promega). The human MeCP2 expression
vector was a kind gift from S. Kudo, Hokkaido Institute, Sapporo, Japan (33).
Generation of transgenic mice. Transgenic mice were generated by standard
techniques (22). The vector sequences were removed from the cyclin A1 pro-
moter-EGFP construct by restriction digestion, and the DNA fragment was
purified. Fertilized eggs were harvested from the oviducts of B6D2F1 (C57BL/
6J 3 DBA)F1 females, and the DNA was microinjected into the pronuclei of
fertilized eggs. The injected eggs were incubated in KSOM (Specialty Media) at
37°C and 5% CO2 until they were transferred to the oviducts of pseudopregnant
females. About 10% of the offspring contained the transgene. The presence of
the transgene was confirmed by PCR and Southern blot analysis. The expression
of the transgene did not impair either survival or fertility of the mice (data not
shown).
Preparation of cells from murine organs for flow cytometric analysis and cell
sorting. The tunica was removed from the testis, and the tubules were teased out
and spread in a 5% collagenase solution in HEPES-buffered modified HTF
medium (Irvine Scientific) for 15 min at 37°C. The tubules were lifted into 1 ml
of enzyme mixture (containing trypsin, collagenase, and DNase)/testis and
minced with sterile needles. The minced tubules were incubated at 37°C for 15
min. The undigested tubules were allowed to settle, and the cell suspension was
aspirated, washed three times by centrifugation at 400 3 g, and resuspended in
6 ml of modified HTF medium. The cells were resuspended in 1 ml of HTF
medium and passed through nylon mesh before flow cytometric analysis and cell
sorting were performed. The kidney cells were prepared in the same way except
that the first collagenase incubation was omitted. Single-cell suspensions from
bone marrow and spleen were obtained by pressing the cells through a mesh.
Analysis of CpG methylation. Bisulfite sequencing was carried out according
to the method described by Clark et al. (8) with minor modifications. Ten
micrograms of sheared genomic DNA was incubated with the bisulfite-hydro-
quinone solution for 6 h. A nested PCR was performed (the primers are listed in
Table 1), and the final PCR product (356 bp) was gel purified. Also, another set
of primers was chosen that exclusively amplified the transgenic cyclin A1 pro-
moter-EGFP construct (Table 1). For analyses of the cell lines, the PCR prod-
ucts were blunt end cloned and 14 to 18 clones were sequenced. Sequences were
obtained from two independent batches of bisulfite-treated DNA and at least two
independent PCRs. In all other cases, the purified PCR products were directly
sequenced using 33P cycle sequencing of nucleotides to obtain an overview of the
methylation pattern of the sense strand of the cyclin A1 promoter.
In vitro methylation and luciferase assay. The cyclin A1 promoter-luciferase
reporter construct was in vitro methylated by SssI (New England Biolabs) fol-
lowing the recommendations of the manufacturer (33). S2 Drosophila cells were
transfected as described previously (42) using 1 mg of either methylated or
mock-methylated luciferase-reporter plasmid, 100 ng of Sp1 expression plasmid,
and 1 mg of a cytomegalovirus–b-galactosidase expression plasmid used for
standardization purposes. One microgram of either human MeCP2 expression
vector or empty vector control was cotransfected. For the experiments using
trichostatin A (TSA), the drug was added 24 h after transfection and analyses
were performed 24 h later. Luciferase experiments were performed in duplicate
and independently repeated three times.
Reverse transcription (RT)-PCR and Southern blotting. Total RNA was pre-
pared using Trizol (Gibco-Life Technologies). The RNA samples were reverse
transcribed using Superscript II (Gibco-Life Technologies) and random hexam-
ers following the recommendations of the manufacturer. Samples without the
addition of Superscript II served as controls. The cyclin A1 PCR was performed
for 28 cycles, and the b-actin PCR was performed for 20 cycles. The PCR
products were run on a 1.5% agarose gel and blotted on a positively charged
nylon membrane. After being cross-linked, the blots were hybridized with inter-
nal oligonucleotides for cyclin A1 and b-actin. Both were labeled with digoxige-
nin that was nonradioactively detected using digoxigenin antibodies coupled to
alkaline phosphatase (Boehringer Mannheim). A subsequent chemilumines-
cence reaction (CDP-Star; Tropix, Bedford, Mass.) was visualized on X-ray film.
Quantitative real-time PCR. The quantitation of mRNA levels for cyclin A1
and the MBD family members was carried out by a real-time fluorescence
detection method (13, 17). The cDNA was prepared as described above and
amplified by PCR in the ABI Prism 7700 sequence detector (PE Biosystems,
Foster City, Calif.). The initial concentrations of template of murine MBD
mRNA were determined by real-time analyses of the amount of PCR product
present in the samples at each PCR cycle as measured by SybrGreen incorpo-
ration. All primer combinations were positioned to span an intron from two
different exons. The primer combinations produced a single product of the
appropriate length as visualized by electrophoresis in a 3% agarose gel. When
genomic DNA was used as a template, no bands were seen after PCR amplifi-
cation. Cyclin A1, murine and human glyceraldehyde-3-phosphate-dehydroge-
nase (GAPDH), human MBD proteins 1 to 4, and MeCP2 were detected by the
59 nuclease assay (38). In brief, oligonucleotide probes annealed to the PCR
products during the annealing and extension steps. The probes were labeled at
the 59 end with VIC (GAPDH probes) or with FAM (all others) and at the 39 end
with TAMRA, which served as a quencher (38). The 59-to-39 nuclease activity of
the Taq polymerase cleaved the probe and released the fluorescent dyes (VIC or
FAM) which were detected by the laser detector of the sequence detector. After
the detection threshold was reached, the fluorescence signal was proportional to
the amount of PCR product generated. The initial template concentration could
be calculated from the cycle number when the amount of PCR product passed a
threshold set in the exponential phase of the PCR. All probes were positioned
across exon-exon junctions. Primer and probe sequences (Table 1) were either
supplied by PE Biosystems (human GAPDH) or designed with Primer Express
software (PE Biosystems) using published sequences (18, 42). Relative gene
expression levels were calculated using standard curves generated by serial di-
lutions of U937 cDNA (human samples) or 32D cell cDNA (murine samples).
The relative amounts of gene expression were calculated by using the expression
of GAPDH as an internal standard. At least three independent analyses were
performed for each gene, and data are presented as the mean 6 standard error
(SE). For analyses of mRNA expression levels of murine MBD proteins, testis
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cells from transgenic mice were sorted by flow cytometry as described above, and
RNA was prepared with Trizol reagent (Gibco). The cDNA from the somatic
organs was obtained from Clontech.
Exposure of HeLa cells to TSA and 5-aza-C. HeLa cells were seeded at low
density in 100-mm-diameter plates. Twenty-four hours after being seeded, the
cells were exposed to 1 mM 5-aza-cytidine (5-aza-C). After 72 h, TSA (final
concentration, 1 mM) was added to the appropriate dishes and incubation was
continued for another 24 h. The cells were directly lysed in Trizol to extract
RNA.
RESULTS
Methylation of the cyclin A1 promoter correlates with non-
expression in somatic cell lines. Tissue-specific expression of
the cyclin A1 gene is tightly regulated. High expression levels
of cyclin A1 in mice and healthy humans are restricted to the
testis. To understand the regulation of cyclin A1 expression, we
recently cloned and characterized the human cyclin A1 pro-
moter. The 59 upstream region of the cyclin A1 gene contains
a CpG island, and the GC content exceeds 90% in a region 60
bp upstream of the transcriptional start site (Fig. 1a). We
analyzed the endogenous human cyclin A1 promoter for CpG
methylation at all 27 CpG dinucleotides located between 2217
and 1117 relative to the transcriptional start site (Fig. 1b and
c). Four cell lines with different concentrations of cyclin A1
mRNA were chosen for these analyses. The myeloid leukemia
cell lines U937 and KCL22 express levels of cyclin A1 that are
detectable by Northern blotting, whereas PC3 and HeLa do
not express cyclin A1 (43). Interestingly, we found a close
correlation between cyclin A1 nonexpression and a high de-
gree of CpG methylation. No methylation was seen in highly
expressing U937 and KCL22 myeloid leukemia cells. Hypom-
ethylation in the leukemic cell lines was clearly restricted to the
CpG island, since a CpG dinucleotide at 1117, which is out-
side of the CpG island, was found to be completely methylated
in each of the cell lines (Fig. 1c).
Silencing of a transgenic cyclin A1 promoter is associated
with de novo methylation in MG63 osteosarcoma cells. Silenc-
ing of transgenes in cell lines involves de novo methylation and
histone deacetylation (51). To analyze whether a transgenic
cyclin A1 promoter would be silenced in cell lines, we con-
structed a cyclin A1 promoter-EGFP transgene that was trans-
fected into MG63 osteosarcoma cells. A population of stable
transfected cells was established by continuous selection in
neomycin-containing medium. These cells were cultured for
a
b c c
FIG. 1. Methylation of the CpG island in the cyclin A1 promoter correlates with loss of expression in somatic cell lines. (a) Distribution of CpG dinucleotides in
the cyclin A1 gene, bp 21299 to 1633. The CpG island of the cyclin A1 promoter extends over 1,200 bp and includes four critically important Sp1 binding sites (marked
Sp1). The main transcriptional start site and the area analyzed by bisulfite sequencing are also indicated. (b) Bisulfite sequencing was carried out according to the
method described by Clark et al. (8) with minor modifications (see Materials and Methods). Shown are the sequencing results for unmodified DNA (U937) and for
bisulfite-treated DNA from a cyclin A1-expressing (U937) and a nonexpressing (HeLa) cell line. The methylated CpG dinucleotides (mCpG) are indicated in HeLa
cells in the area surrounding the two most proximal Sp1 sites of the cyclin A1 promoter. (c) A total of 27 CpG dinucleotides (14 to 18 independent clones) were analyzed
for methylation in each of the four cell lines, which differ in their levels of cyclin A1 expression. The percentage of methylation at each CpG is indicated. The last CpG,
at 1117, is outside the CpG island and was found to be completely methylated in all of the cell lines. The order of the degree of cyclin A1 expression in these cell lines
is U937.KCL22.PC3.HeLa, and cyclin A1 expression in PC3 and HeLa is not detectable by Northern blot analysis (43).
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several months, and the majority of cells lost expression of the
transgene over time (Fig. 2a). EGFP-expressing and nonex-
pressing cells were sorted by flow cytometry, and the DNAs of
these cells were subjected to analysis of the methylation status
of the transgenic promoter. To avoid amplification and analysis
of the endogenous cyclin A1 gene, a different set of primers
that included the EGFP gene was used in these experiments
(Table 1). Interestingly, no CpG methylation of the transgenic
promoter was observed in the EGFP-expressing cells, whereas
a high degree of methylation of all analyzed CpG dinucleotides
was present in the cell fraction containing the silenced trans-
gene (Fig. 2a). These findings suggest that methylation of the
cyclin A1 promoter is associated with gene silencing in cell
lines.
MeCP2 can repress transcription from the methylated cy-
clin A1 promoter in Drosophila cells. Transcriptional repres-
sion of CpG methylation can be mediated by members of the
MBD family of proteins (19). The methyl-CpG binding protein
2 (MeCP2) was the first member of this family that was shown
to repress transcription by recruiting HDAC activity to meth-
ylated promoters (44, 45). For example, the human leukosialin
gene is negatively regulated by MeCP2 when the leukosialin
promoter is methylated (33). Leukosialin (similar to cyclin A1)
is expressed in a tissue-specific manner, and its transcriptional
activity depends on the Sp1 transcription factor. S2 Drosophila
cells do not express endogenous MeCP2, and transfection of
DNA into these cells leads to rapid chromosomal integration.
Using these cells, we analyzed whether the methylated cyclin
A1 promoter could be suppressed by cotransfected MeCP2
(Fig. 2b). Upon transfection of in vitro-methylated cyclin A1
promoter constructs into Drosophila cells, threefold repression
of reporter activity was detected in the absence of MeCP2.
When MeCP2 was coexpressed with the methylated cyclin A1
promoter construct, promoter activity was inhibited by 12-fold,
indicating that MeCP2 strongly suppressed transcriptional ac-
tivation of the methylated cyclin A1 promoter (Fig. 2b). The
effects of MeCP2 on the methylated cyclin A1 promoter were
shown to depend on HDAC activity, since inhibition of histone
deacetylase activity restored promoter activity in a dose-depen-
dent manner (Fig. 2c).
MBD gene expression in human cancer cell lines. We ana-
lyzed whether the known MBD family members were ex-
pressed in the human cell lines and would be able to be in-
volved in regulation of the methylated cyclin A1 promoter.
Protein expression of MeCP2 in HeLa cells has been reported
to be very low (46, 47). We tested protein expression of MeCP2
in HeLa cells using a polyclonal rabbit antibody, and we con-
sistently detected a weak band at 84 kDa (data not shown).
Since several other bands were present on the Western blot, we
decided to analyze the expression of MeCP2 and MBD-1 to -4
by quantitative real-time PCR (Fig. 3). MeCP2 mRNA was
clearly present in all four cell lines, and the differences in the
MeCP2 mRNA levels were very small. In addition, we were
able to detect expression of MBD-1 to -4 mRNA in the four
cell lines. The greatest differences (up to sixfold) in expression
were detected for MBD-1 and MBD-3, whereas expression of
MBD-2 and MBD-4 was very similar in the different cell lines.
Inhibitors of histone deacetylation but not inhibitors of
methylation alone induce cyclin A1 mRNA in nonexpressing
HeLa cells. Next, we analyzed whether changes in either the
degree of methylation or the acetylation status of histones
could induce cyclin A1 expression in nonexpressing cells. HeLa
cells were exposed to either the demethylation agent 5-aza-C
(1 mM) for 96 h and/or to the inhibitor of histone deacetylases,
TSA (1 mM) for 24 h. Whereas 5-aza-C did not have significant
effects on the morphology of HeLa cells, TSA led to an obvious
change in cell shape, and the cells showed signs of differenti-
ation (Fig. 4). Exposure of HeLa cells to 5-aza-C alone did not
lead to significant induction of endogenous cyclin A1 expres-
sion (Fig. 5a), although cyclin A1 promoter methylation de-
creased significantly after HeLa cell exposure to 5-aza-C (Fig.
5b). These results were confirmed using concentrations of
5-aza-C as high as 10 mM (data not shown). Also, 5-aza-deoxy-
cytidine, another demethylation reagent, failed to induce cyclin
A1 in HeLa cells as well (data not shown). TSA (1 mM) led to
a strong induction of endogenous cyclin A1 expression (Fig.
5a). Similar but weaker induction was detected with 250 nM
TSA (data not shown). Only slightly stronger induction of
cyclin A1 was observed when the cells had been preexposed to
5-aza-C. Interestingly, demethylation also occurred in HeLa
cells exposed to either TSA alone or the combination of TSA
and 5-aza-C (Fig. 5b). However, demethylation itself was not
associated with the increase in cyclin A1 expression, since
demethylation by 5-aza-C alone did not lead to induction of
cyclin A1 expression.
A 1.3-kb fragment of the cyclin A1 promoter directs tissue-
specific expression in testes of transgenic mice. Methylation of
the cyclin A1 gene was associated with nonexpression in mam-
malian cell lines, but these observations did not elucidate
whether methylation had a causal role in transcriptional re-
pression and in controlling the tissue specificity of the pro-
moter. This led us to investigate whether the 1.3-kb fragment
of the cyclin A1 promoter could direct tissue-specific expres-
sion in vivo and whether expression in differentiated tissues in
vivo would be influenced by CpG methylation. We established
four lines of transgenic mice that carried the cyclin A1 pro-
moter-EGFP reporter construct previously used to generate
the stable MG63 cell line. Expression of the transgene was
analyzed by fluorescence microscopy and flow cytometry in a
wide variety of cell types and tissues. Strong EGFP expression
was seen in the testes of all transgenic murine lines. EGFP
expression in the testis was confined to male germ cells during
spermatogenesis (Fig. 6). Neither Leydig cells nor Sertoli cells
expressed significant levels of EGFP. During spermatogenesis,
type I spermatogonia at the basal membrane did not express
cyclin A1. Intermediate expression was seen in later stages of
spermatogonia and in spermatocytes in the early phases of the
first meiotic division. A sharp increase in EGFP expression was
observed during the first meiotic division, and levels of EGFP
subsequently remained very high. No leaky expression was
noted in any of the other cell types in the testis, indicating that
the 1.3-kb fragment directed very strong and highly specific
expression. This pattern of expression in testes was identical in
all four transgenic lines. The observed expression pattern
matches murine cyclin A1 RNA in situ hybridization results
(54). Also, protein expression of the endogenous cyclin A1
gene in the testis was found only in cells expressing EGFP (Fig.
7), verifying the specificity of the cyclin A1 promoter in vivo.
Furthermore, the identical transgene expression pattern in tes-
tes of different murine lines indicated that the cyclin A1 pro-
moter was able to direct tissue-specific expression in the testis
independently of the chromosomal integration site.
Methylation does not suppress testis-specific expression of
the cyclin A1 promoter. The methylation and activity status of
a transgene is thought to be largely determined by either the
chromatin structure at the site of integration, the cis-acting
sequences in the transgene, and/or the influence of a locus
control region (5, 31, 49). Transgene activity has also been
reported to be associated with hypomethylation (51). There-
fore, we tested whether methylation of the promoter would
differ in expressing and nonexpressing cells. Analysis of meth-
ylation of the CpG dinucleotides showed that all CpGs were
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FIG. 2. Methylation is associated with silencing of a cyclin A1 promoter-EGFP transgene in MG63 cells, and MeCP2 represses the methylated cyclin A1 promoter
by an HDAC-dependent mechanism. (a) MG63 osteosarcoma cells were stably transfected with a cyclin A1 promoter-EGFP construct. After 2 months of continuous
culture, a fraction of neomycin-resistant cells had lost expression of EGFP. Both populations were sorted by flow cytometry and analyzed for CpG methylation of the
cyclin A1 promoter transgene. Specific primers were designed for the promoter-EGFP construct to avoid analysis of the endogenous cyclin A1 locus. Strong methylation
was observed in nonexpressing cells, whereas negligible or very low levels of methylation were observed in expressing cells. (b) Methylated (1) or mock-methylated
(2) reporter constructs were transfected into S2 Drosophila cells along with an Sp1 expression plasmid and either an empty vector (2) or an MeCP2 expression vector
(1). Fold repression was calculated as 1/relative activity, with the activity of the control set as 1. The results are shown as the mean 1 SE of three independent
experiments. (c) TSA relieves MeCP2-mediated repression of the methylated cyclin A1. Twenty-four hours after transfection of the methylated construct and the
MeCP2 expression vector, TSA was added in different concentrations as indicated. The next day, luciferase activities were analyzed.
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either strongly methylated or nonmethylated in a particular
organ. Also, the variation in methylation patterns between
different organs was very small (Table 2). In addition, methyl-
ation patterns were stable in adult mice from the same line
(data not shown). Analysis of the methylation status of the
human cyclin A1 promoter in the testes of the transgenic mice
showed that the promoter and the transgene were not meth-
ylated in the testes of two lines (no. 2 and 3) (Table 2). How-
ever, the promoter and the transgene were heavily methylated
in the testes of the two other lines (no. 1 and 4). No difference
could be found between the EGFP expression patterns in the
testes of the murine lines with and without CpG methylation.
FIG. 3. mRNA expression levels of MBD protein family members in human cancer cell lines. Expression levels of the indicated MBD family members were
determined by quantitative real-time PCR as described in Materials and Methods. The indicated relative gene expression shows expression levels that were standardized
using expression of GAPDH as a standard. Expression levels were determined independently at least three times and are shown as the mean 1 SE.
FIG. 4. Inhibitors of histone deacetylases alter the phenotypes of HeLa cells. HeLa cells were exposed to 5-aza-C for 96 h and to TSA for 24 h. Exposure of cells
to 5-aza-C (c) did not induce morphological changes compared to control cells (a). TSA alone (b) or in combination with 5-aza-C (d) led to cell death and signs of
differentiation, such as spindle cell formation.
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To confirm that EGFP was highly expressed despite methyl-
ation in these male germ cells, testis cells were disaggregated
and sorted by flow cytometry (Fig. 8a). Bisulfite sequencing
confirmed that methylation of the cyclin A1 promoter in germ
cells did not inhibit expression of the transgene in the testis
(Fig. 8b). The degree of methylation was similar in EGFP-
expressing and non-EGFP-expressing cells of the same trans-
genic line. Accordingly, nonexpression of EGFP appropriately
occurred in the absence of methylation. More surprisingly,
strong methylation of all analyzed CpG dinucleotides (total,
27) surrounding the transcriptional start site neither sup-
pressed nor altered transcriptional activity of the transgenic
cyclin A1 promoter (Fig. 8b).
Methylation is not necessary to suppress transcription from
the cyclin A1 promoter in nonexpressing cells from most or-
gans. One of the murine transgenic lines without methylation
in the testis (no. 3) showed promoter methylation in the kidney
and bone marrow but not in the liver. This line showed EGFP
expression exclusively in the testis (Table 2). The transgenic
murine line no. 2 did not show a significant degree of methyl-
ation of the transgenic cyclin A1 promoter anywhere and ex-
pressed EGFP in a subset of cells in the kidney (25%), spleen
(10%), and bone marrow (16%). Expression of EGFP in these
organs was clearly restricted to certain cell types, such as the
podocytes and collecting ducts in the kidneys and B-cell sub-
populations in the spleen and bone marrow (Fig. 9). A minor
percentage of myeloid progenitors expressed EGFP as well.
Expression of EGFP in these organs did not reflect expression
of the endogenous murine cyclin A1 gene, as evidenced by
Western blotting (Fig. 7) and by RT-PCR of sorted cell pop-
ulations (data not shown). The correct sorting into EGFP-
expressing and non-EGFP-expressing cells was confirmed by
Western blot analysis with anti-EGFP antibody (not shown).
Although a fraction of the cells in the kidneys, spleen, and
bone marrow expressed EGFP, the majority of cells did not. In
addition, no EGFP expression was found in many other organs
(e.g., skin, muscle, lung, and gut), indicating that methylation
was not necessary to suppress cyclin A1 promoter activity, at
least in most cells. On the other hand, expression outside the
testis was restricted to the transgenic mouse line, which did not
have methylation of the CpG island of the cyclin A1 promoter.
One of the reasons that methylation of the cyclin A1 promoter
FIG. 5. (a) Induction of endogenous cyclin A1 expression by TSA. Induction
of cyclin A1 gene expression by 5-aza-C and TSA was analyzed by quantitative
real-time PCR as well as by conventional RT-PCR followed by hybridization.
The plot for the amplification of cyclin A1 cDNA from HeLa cells that were
exposed to the indicated drugs is shown. The x axis shows the cycle number, and
the y axis shows the changes in fluorescence compared to baseline values. These
samples contained similar amounts of cDNA, as demonstrated by analysis of
GAPDH expression (not shown). The inset shows conventional RT-PCR for
cyclin A1 (28 cycles) and b-actin (20 cycles). PCR was followed by Southern
blotting and nonradioactive detection with an internal oligonucleotide. TSA, but
not 5-aza-C, led to a strong induction of cyclin A1 in HeLa cells. (b) 5-aza-C and
TSA lead to demethylation of the cyclin A1 promoter in HeLa cells. To analyze
the effects of 5-aza-C and TSA on the methylation status of the endogenous
cyclin A1 promoter in HeLa cells, genomic DNA was prepared, bisulfite treated,
PCR amplified, and sequenced (see Materials and Methods). The percentage of
methylation at 27 CpG dinucleotides of the cyclin A1 promoter is indicated. Two
independent DNA preparations and PCR amplifications were performed and
cloned, and at least 10 independent clones were sequenced.
FIG. 6. Testis-specific expression of the cyclin A1 promoter in transgenic
mice. Transgenic mouse lines were established using the cyclin A1 promoter-
EGFP reporter plasmid described in the legend to Fig. 2. Frozen sections from
testes of adult mice were cut, rinsed in phosphate-buffered saline for 10 min, and
analyzed by confocal laser scanning microscopy. (a) No fluorescence was ob-
served in testicular tubuli of control mice. (b and c) In contrast, strong and highly
specific expression of EGFP was detected in the testes of the transgenic mice.
Maximal EGFP expression was observed during and after the first meiotic divi-
sion, and a weaker staining was present in spermatogonia. The fluorescence of
the interstitial Leydig cells in panel c is unrelated to EGFP expression but
depends on the accumulation of lipids. The wavelength of the emitted light is
different from that of EGFP. Magnifications are 3380 (a and b) and 395 (c).
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did not repress promoter activity in the testes could be that
relevant MBD family members are not expressed in germ cells.
To test this hypothesis, we analyzed expression levels of
MeCP2 and MBD family members in EGFP-expressing male
germ cells as well as in somatic organs from mice (Fig. 10).
While mRNA from MBD-1 to -4 and the testis-specific splice
variant of MBD-2 were present in EGFP-expressing testis
cells, MeCP2 expression was very low in male germ cells. The
testis-specific variant of MBD-2 showed higher expression in
EGFP1 testis cells than in EGFP2 testis cells.
DISCUSSION
Cyclin A1 is essential for spermatogenesis and is expressed
at very high levels in pachytene spermatocytes (37). We have
previously shown that human cyclin A1 protein directly inter-
acts with E2F-1 and the Rb family of proteins, indicating its
potential role in the cell cycle of somatic cells (65). In contrast
to other cyclins that regulate the cell cycle during S and G2/M
phases, cyclin A1 displays a highly restricted pattern of expres-
sion (54, 64). To analyze the mechanisms that determine cyclin
A1 expression, we have recently cloned the promoter region of
the human cyclin A1 gene (42). Upon transient transfection,
FIG. 7. EGFP expression in testes but not in somatic cells of transgenic mice
correlates with endogenous cyclin A1 expression. Testis, spleen, and bone mar-
row cells from transgenic animals were sorted by flow cytometry into expressing
(1) and nonexpressing (2) populations. Testis cells were further divided into
highly (bright) and weakly (dim) expressing populations. A total of 2 3 105 cells
of each population were lysed in sodium dodecyl sulfate sample buffer, and
samples were run on a 10% Tris-HCl gel. The blots were probed with anti-cyclin
A1 rabbit polyclonal antibody as described previously (52). The strong back-
ground seen for the spleen and bone marrow cells relates to the much longer
exposure necessary to visualize the bands. Results similar to those for the spleen
and bone marrow cells were obtained for EGFP-expressing kidney cells.
FIG. 8. Expression of EGFP in germ cells of transgenic mice is independent
of methylation of the transgenic cyclin A1 promoter. (a) To analyze whether the
CpG methylation status differed in EGFP-expressing and non-EGFP-expressing
cells in the testis, the testes of two murine lines (no. 2 and 4) were enzymatically
disaggregated and sorted by flow cytometry in expressing (1) and nonexpressing
(2) cells. Shown is a representative flow cytometry analysis of testicular cells
from murine line no. 2. (b) Genomic DNA of the sorted testicular cells was
analyzed for CpG methylation. In murine line no. 2, CpG methylation was not
seen in EGFP-expressing (1) or non-EGFP-expressing testicular cells (2). In
murine line no. 4, EGFP-expressing cells were completely methylated at all CpG
dinucleotides. The methylation status did not differ in EGFP-expressing (1) and
non-EGFP-expressing (2) testicular cells.
TABLE 2. CpG methylation of the human cyclin A1 promoter and expression of EGFP in transgenic murine linesa
Line
Testis Kidney Liver Bone marrow Spleen Muscle
mCpG EGFP (%) mCpG EGFP (%) mCpG EGFP (%) mCpG EGFP (%) mCpG EGFP (%) mCpG EGFP (%)
1 1 70 1 0 1 0 1 0 ND 0 ND 0
2 2 70 2 25 2 0 2 10 2 16 2 0
3 2 70 1 0 2 0 1 0 ND 0 ND 0
4 1 70 1 0 1 0 1 0 1 0 1 0
a Organs from adult mice of the four transgenic murine lines (no. 1 to 4) were obtained, and the methylation pattern of the transgenic cyclin A1 promoter was
determined by direct sequencing of PCR products derived from bisulfite-treated genomic DNA. A total of 23 CpG dinucleotides (2217 to 129) were analyzed. The
CpG dinucleotides within one organ from one line were found to be either completely methylated (1) or nonmethylated (2). Methylation patterns were consistent
among mice from the same transgenic line. The percentages indicate the fraction of EGFP-expressing cells in the respective organs of the murine lines. Expression
outside the testis was seen only when the promoter of the transgene was not methylated. ND, not determined.
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the cyclin A1 promoter was active in somatic-cell lines from
various tissues, even in those that do not normally express
cyclin A1 (including HeLa and PC3 cells) (43).
Cyclin A1 promoter activity critically depends on four Sp1
binding sites that are located between 60 and 120 bp upstream
of the main transcriptional start site (42). Transcriptional ac-
tivity is enhanced by c-myb, which is expressed in hematopoi-
etic progenitors and myeloid leukemia cells (43). The Sp1
FIG. 9. Aberrant expression of EGFP was found in kidneys and B lymphocytes from transgenic murine line no. 2. (a) Expression of EGFP in kidneys of murine
line no. 2 is tightly restricted to podocytes in glomeruli and to collecting ducts. Nonfluorescent structures detected by phase-contrast microscopy were colored red to
allow a better visualization of the overall structure of the kidney. (b) B lymphocytes from the spleen of a transgenic mouse (line no. 2) and from a negative-control
mouse were stained using anti-CD19 monoclonal antibody labeled with phycoerythrin (PE). About 40% of the B cells of murine line no. 2 expressed EGFP. Note that
the population that does not express CD19 also does not express EGFP. (c) Bone marrow from a control mouse and a mouse of line no. 2 were analyzed by flow
cytometry without antibody staining. The forward scatter properties distinguish cell populations according to their sizes. The very small percentage of hematopoietic
stem cells (,1%) precludes us from determining whether EGFP expression in these cells reflects the endogenous cyclin A1.
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transcription factor that is essential for cyclin A1 promoter
activity is ubiquitously expressed, and the cyclin A1 promoter
does not show tissue specificity in transient transfections.
These findings hinted at a role of epigenetic regulation in the
tissue-specific expression of cyclin A1.
Methylation of CpG dinucleotides has been shown to lead to
transcriptional repression by several mechanisms. Binding of
transcription factors can be inhibited by CpG methylation; for
example, c-myb did not bind to its consensus binding site when
it was methylated (32). On the other hand, Sp1 binding is not
inhibited by CpG methylation (16, 23). Members of the MBD
family of proteins bind to methylated CpGs in genomic DNA
and confer the biological effects of methylation (19, 39).
MeCP2 as well as MBD-2, which is a member of the MeCP1
complex, can repress transcription by recruiting corepressors
and histone deacetylase activity (28, 45, 47). The MeCP1 com-
plex, identified several years ago, mediates repression of
heavily methylated DNA (4, 40). MeCP2 is essential for em-
bryonic development and can bind to single methylated CpG
dinucleotides (44, 55). Among the other members of the MBD
family of proteins, MBD-4 is involved in DNA repair mecha-
nisms, whereas the functions of the other members are cur-
rently unknown (20).
To test the hypothesis that MBD family proteins are in-
volved in transcriptional silencing of the methylated cyclin A1
promoter in tumor cell lines, we examined the effects of
MeCP2 on the transcriptional activity of a methylated cyclin
A1 promoter construct. Our data demonstrate that the meth-
ylated cyclin A1 gene can be repressed by a MeCP2-mediated
mechanism. However, MeCP2 has been reported to be ex-
pressed at very low levels in HeLa cells that do not express
cyclin A1 (47). Our own Western blotting experiments con-
firmed the low levels of MeCP2 protein expression in HeLa
cells (data not shown). Using quantitative real-time PCR with
the 59 nuclease assay, we demonstrated that MeCP2, as well as
the other MBD family members, was expressed at the mRNA
level in different human cell lines. No significant differences in
MBD mRNA expression levels were found between adherent
(HeLa and PC3) and leukemic (U937 and KCL22) cell lines.
These findings indicate that in the absence of MeCP2, the
other MBD family members, especially MBD-2, might be in-
volved in transcriptional repression of genes with methylated
promoters, including cyclin A1.
Inhibition of histone deacetylase activity restored cyclin A1
promoter activity in the insect cell transfection assay and in-
duced cyclin A1 gene expression from the endogenous pro-
moter in otherwise nonexpressing HeLa cells. Demethylation
of the promoter in HeLa cells had only minor effects on cyclin
A1 expression. These findings indicate that stable repression of
the cyclin A1 promoter is mediated by histone deacetylation-
dependent mechanisms. These data differ from those obtained
for several other methylated promoters where demethylation
of promoter regions by 5-aza-C was the dominant mechanism
that led to expression of silenced genes (7). MBD family mem-
bers that recruit HDAC activity to methylated promoters are
likely to play a role in transcriptional repression of the cyclin
A1 gene in solid-tumor cell lines.
The close correlation between methylation and silencing of
the cyclin A1 promoter suggests that hypomethylation of the
promoter is important for transcriptional activity of the cyclin
A1 promoter in the leukemia cell lines. Despite the presence of
aberrant methyltransferase activity (25, 30), tumor cells show
hypomethylation of the promoter regions of genes that pro-
mote growth and inhibit apoptosis (12, 15). Transcriptional
activity of a promoter can preserve its hypomethylated status
through binding sites for specific transcription factors, such as
Sp1 (5). In addition, cyclin A1 induction by TSA in HeLa cells
was correlated with a loss of cyclin A1 promoter methylation.
FIG. 10. Expression levels of MBD family members in murine tissues. The mRNA levels of murine MBD proteins were determined by quantitative real-time
RT-PCR as described in Material and Methods. EGFP-expressing (GFP1) and non-EGFP-expressing (GFP2) testicular cells from transgenic mice were sorted by flow
cytometry before the preparation of RNA. MeCP2 expression was very low in EGFP-expressing male germ cells. On the other hand, MeCP2 was robustly expressed
in EGFP-negative testis cells from the same mice. Expression levels of MBD-1 to MBD-4 and the testis-specific variant of MBD-2 showed only minor differences in
expression between the two testicular cell populations. The error bars represent the SE.
3326 MU¨LLER ET AL. MOL. CELL. BIOL.
To analyze whether methylation plays a role in directing
tissue-specific cyclin A1 expression in vivo, we generated mice
that were transgenic for the cyclin A1 promoter driving an
EGFP reporter gene. We chose to analyze the association
between the status of the transgene methylation and the ex-
pression of the reporter gene for several reasons. Since micro-
injection of foreign DNA leads to random integration, the
methylation status of the transgene varies in different trans-
genic lines. This provided the opportunity to study the effects
of methylation versus nonmethylation of the cyclin A1 pro-
moter on gene expression rather than the pure correlation
between expression and methylation of the gene. Correlative
data between expression and methylation of endogenous genes
rarely provide hard evidence either in favor of or against a role
for methylation in directing tissue-specific expression (61). A
pure correlation is also unable to prove whether methylation is
a primary or a secondary event in silencing the expression of a
gene.
Using transgenic mice as a model system, we demonstrated
that transcriptional repression of cyclin A1 promoter activity
could be established in almost all organs without CpG meth-
ylation of the transgenic promoter. In addition, the presumed
suppressive effect of CpG methylation is specific to the cell
type, since the correct patterns of expression in the testis were
detected in two murine lines despite high levels of CpG meth-
ylation of the transgenic cyclin A1 promoter. Expression pat-
terns in male germ cells did not differ between transgenic lines
with and without CpG methylation of the transgenic promoter.
To our knowledge, this is the first time that a transgenic pro-
moter in a whole organism has been shown to be active despite
strong methylation.
The nonsuppressive effect of methylation in male germ cells
might be explained by the presence of specific activating fac-
tors that could override the suppressive activity of methylation.
Alternatively, corepressors that are necessary for methylation-
mediated repression could be either inactive or missing in male
germ cells. The overall degree of DNA methylation increases
during spermatogenesis and is very high in mature sperm com-
pared to other cells (29, 41). The absence of repressing factors
could be associated with the generally less tightly regulated
repression of gene expression that occurs during meiosis (10,
26). In addition, MeCP2 activity is barely detectable in adult
testes (40). We used quantitative real-time PCR to demon-
strate the absence of MeCP2 mRNA expression in EGFP-
expressing male germ cells. Interestingly, MeCP2 mRNA was
highly expressed in murine testis cells without detectable cyclin
A1 promoter activity. This close correlation suggests that the
absence of MeCP2 expression is a possible explanation for the
nonsuppressive effect of methylation on cyclin A1 promoter
activity in male germ cells. Expression of all other MBD family
members, including the testis-specific variant of MBD-2, could
be demonstrated in EGFP-positive and -negative cells. Taken
together, our finding that methylation did not suppress cyclin
A1 promoter activity in male germ cells suggests that the sup-
pressive role of methylation for some genes might be cell type
specific.
In somatic cells, transcriptional repression of the transgenic
promoter appropriately occurred irrespective of the methyl-
ation pattern in most of the tissues, showing that methylation
is not necessary for transcriptional repression in most differ-
entiated tissues. Since the cyclin A1 promoter was active in
transient transfections in each of the cell types examined, in-
cluding primary cells, the repression of the transgenic cyclin A1
promoter is most likely based on a repressor mechanism that
alters the chromatin structure. A specific repressor protein
might bind to an unidentified binding site and recruit the
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relevant corepressors and histone deacetylases. The nature of
this presumed repressor is unknown. One repressor protein,
c-mos, has been described that directs tissue-specific repres-
sion outside of the testis by strong suppression of germ cell-
specific promoters in somatic cells (63). However, the c-mos
repressor is highly repressive even in transient transfections;
thus, this mechanism is unlikely to be relevant for the cyclin A1
promoter.
Aberrant expression of the transgene was seen in kidney
podocytes and collecting ducts and B lymphocytes of murine
line no. 2, the only transgenic line without CpG methylation in
any of the analyzed organs. In contrast to expression in the
testis, EGFP expression in these cells did not match expression
of the endogenous murine cyclin A1 gene (Fig. 7). The very
low levels of expression of cyclin A1 in B cells were confirmed
by RT-PCR analysis of several B-lymphocyte subpopulations
(data not shown). The expression pattern of the murine line
no. 2 might be related to the absence of CpG methylation of
the transgenic promoter and/or to the influence of a locus
control region that is located close to the chromosomal inte-
gration site of the transgene (31, 49). Methylation might have
a role in suppression of cyclin A1 promoter activity in these cell
populations. On the other hand, methylation is neither neces-
sary nor sufficient to direct tissue-specific gene expression in all
other organs that we analyzed (Table 3).
Taken together, these data show that methylation of the
cyclin A1 promoter correlates with nonexpression of the en-
dogenous cyclin A1 gene in somatic cell lines. Members of the
MBD family of proteins, such as MeCP2, might be involved in
transcriptional repression of the methylated cyclin A1 pro-
moter. Tissue-specific repression of the cyclin A1 promoter in
differentiated organs can occur independently of CpG methyl-
ation. Finally, even strong methylation does not necessarily
lead to transcriptional repression, since cyclin A1 promoter
activity in male germ cells cannot be repressed by a high degree
of methylation.
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